Cerevance said it will present results from its Phase 2 ASCEND trial of solengepras at the 2025 International Congress of Parkinson’s Disease and Movement Disorders, taking place October 5–9 in Honolulu. According to the company, the data include assessments of functional and non-motor outcomes, alongside safety findings.
Solengepras is a non-dopaminergic GPR6 receptor inhibitor being studied for use in early-stage Parkinson’s disease. The company claims the 12-week ASCEND study demonstrated evidence of potential benefit in functional and non-motor symptoms, and that solengepras was generally well tolerated with a low rate of dopaminergic side effects.
The presentation (Abstract #942) is scheduled for October 6 at 12:30 p.m. HST in Room 312 of the Hawaii Convention Center. The presenter is Stuart Isaacson, MD, Director and Founder of the Parkinson’s Disease and Movement Disorders Center of Boca Raton.
Cerevance said solengepras is intended to complement existing levodopa and other Parkinson’s medications by targeting the indirect pathway via GPR6, aiming to improve both motor and non-motor symptoms without directly altering dopamine signaling. The company added that solengepras is now in Phase 3 development (ARISE trial) as a once-daily oral adjunctive therapy.
Cerevance focuses on cell type–specific therapies for neurodegenerative and metabolic disorders, using its NETSseq platform to identify novel targets. Solengepras is its lead program; other investigational therapies in its pipeline include CVN766 (for binge eating disorder and schizophrenia) and CVN293 (targeting KCNK13).
